cognitive cybersecurity intelligence

News and Analysis


The future of primary biliary cholangitis treatment

Ipsen has presented long-awaited phase three results for elafibranor, a new class of medication for Primary Biliary Cholangitis. The disease, a genetic chronic liver condition, primarily affects women. Symptoms, which can take years to present, include fatigue and joint pain. Ipsen’s Jennifer Schranz noted that 51% of patients involved in the ELATIVE trial experienced significant benefits compared to 4% taking a placebo.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts